Transparency Market Research Report Added "Pulmonary Arterial Hypertension (PAH) Market" to its database.

Albany, NY -- (SBWire) -- 09/22/2017 --The global PAH market is estimated to reach a valuation of US$5.19 bn by the end of 2020, expanding at a tremendous CAGR of 17.90% between 2014 and 2020.

According to the market report, the global PAH market has been evaluated on the basis of drug classes and regional distribution. Prostacyclin, prostacyclin analogs, PDE-5 inhibitors, ERAs, and sGC stimulators are the key drugs available in the global market to treat PAH. ERAs led the global market in 2013, accounting for a market share of 55.8% in terms of revenue.

Analysts, however, have predicted that the market for prostacyclin and prostacyclin analogs will surpass the ERAs market by the end of the forecast period. The launch of the recently approved Orenitram is likely to propel this market segment during the forecast period. The approval for Uptravi, which is slated in Q1 of 2016, is also anticipated to add to the market segment's growth prospects, notes the research study.North America, Europe, Asia Pacific, and the Rest of the World are the key regional markets for pulmonary arterial hypertension across the world. Among these, the PAH market in North America led the global market with a share of 44.6% in 2013 and was closely followed by the Europe PAH market.

Request to view Sample Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=1181

Over the forecast period, both these regional markets are expected to exhibit remarkable growth, owing to the availability of newly-approved PAH drugs as well as products waiting to gain approval in these markets.The Asia Pacific market for PAH is also projected to show significant development in the next few years. India, China, Japan, New Zealand, and Australia are likely to present opportunity-rich markets for enterprises operating in the global PAH market. On the other hand, the Rest in the World PAH market is facing severe challenges, owing to the low awareness level pertaining to the detection and treatment of pulmonary arterial hypertension, states the market study.

Request to Download TOC of the Report: http://www.transparencymarketresearch.com/report-toc/1181

The major players operating in the global market for pulmonary arterial hypertension are Actelion Pharmaceuticals Ltd., Gilead Sciences Inc., Bayer HealthCare, GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, and United Therapeutics Corp., states the research report.

Global Pulmonary Arterial Hypertension (PAH) Market Report is available @ US$ 5795 : http://www.transparencymarketresearch.com/checkout.php?rep_id=1181

About Transparency Market Research
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMR's experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/